BlackRock Amends Catalyst Pharma Stake (SC 13G/A)

Ticker: CPRX · Form: SC 13G/A · Filed: 2024-01-22T00:00:00.000Z

Sentiment: neutral

Topics: institutional-ownership, passive-investment, amendment, pharmaceuticals

TL;DR

**BlackRock updated its passive stake in Catalyst Pharma; watch for market reaction.**

AI Summary

BlackRock Inc. filed an amended SC 13G/A on January 22, 2024, indicating a change in their ownership of Catalyst Pharmaceuticals Inc. common stock as of December 31, 2023. This filing, Amendment No. 7, shows BlackRock's updated passive investment stake in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal their confidence (or lack thereof) in a company's future prospects, potentially influencing other investors.

Why It Matters

This filing updates BlackRock's passive ownership in Catalyst Pharmaceuticals, providing transparency on a major institutional investor's position, which can influence market sentiment.

Risk Assessment

Risk Level: low — This is a routine update from a passive investor and does not indicate any immediate significant risk or opportunity.

Analyst Insight

Investors should note BlackRock's continued passive interest in Catalyst Pharmaceuticals, but this filing alone doesn't suggest a need for immediate action. It's a routine update, not a change in investment strategy.

Key Players & Entities

FAQ

What type of filing is this document?

This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7)' sections.

Who is the reporting person in this filing?

The reporting person, or the entity that filed this document, is BlackRock Inc., as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.

What is the subject company whose securities are being reported?

The subject company is CATALYST PHARMACEUTICALS, INC., as specified under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC.' and 'CATALYST PHARMACEUTICALS INC (Name of Issuer)'.

What was the date of the event that triggered this filing?

The date of the event which requires the filing of this statement was December 31, 2023, as stated under '(Date of Event Which Requires Filing of this Statement)'.

Under which rule was this Schedule 13G filed?

This Schedule 13G was filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox.

From the Filing

0001086364-24-001109.txt : 20240122 0001086364-24-001109.hdr.sgml : 20240122 20240122155212 ACCESSION NUMBER: 0001086364-24-001109 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240122 DATE AS OF CHANGE: 20240122 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-82644 FILM NUMBER: 24548742 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc. CENTRAL INDEX KEY: 0001364742 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] ORGANIZATION NAME: 02 Finance IRS NUMBER: 320174431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 50 HUDSON YARDS CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-810-5300 MAIL ADDRESS: STREET 1: 50 HUDSON YARDS CITY: NEW YORK STATE: NY ZIP: 10001 FORMER COMPANY: FORMER CONFORMED NAME: BlackRock, Inc. DATE OF NAME CHANGE: 20060929 FORMER COMPANY: FORMER CONFORMED NAME: New BlackRock, Inc. DATE OF NAME CHANGE: 20060601 SC 13G/A 1 us14888u1016_012224.txt us14888u1016_012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) CATALYST PHARMACEUTICALS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 14888U101 -------------------------------------------------------- (CUSIP Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 14888U101 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 15666990 (6) Shared voting power 0 (7) Sole dispositive power 15821401 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 15821401 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 14.8% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- CATALYST PHARMACEUTICALS INC Item 1(b) Address of issuer's principal executive offices: ---------------------------------------------

View on Read The Filing